Switch to:
Alexion Pharmaceuticals Inc (NAS:ALXN)
Research and Development
$514 Mil (TTM As of Dec. 2014)

This is the expense the company spent on research and development. Alexion Pharmaceuticals Inc's research and development for the three months ended in Dec. 2014 was $129 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2014 was $514 Mil.


Definition

This is the expense the company spent on research and development.

Alexion Pharmaceuticals Inc Research & Development for the trailing twelve months (TTM) ended in Dec. 2014 was 191.457 (Mar. 2014 ) + 92.554 (Jun. 2014 ) + 100.661 (Sep. 2014 ) + 129.11 (Dec. 2014 ) = $514 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Alexion Pharmaceuticals Inc Annual Data

Jul05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
Research & Development 918369638298137223317514

Alexion Pharmaceuticals Inc Quarterly Data

Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14Sep14Dec14
Research & Development 54637569888619193101129
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK